AC
ALNY icon

Aaron Cowen’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aaron Cowen’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,370
Closed -$2.53M – 99
2025
Q1 		$2.53M Buy
+9,370
New +$2.41M 0.09% 73
2024
Q4 		– Sell
-13,824
Closed -$3.8M – 99
2024
Q3 		$3.8M Sell
13,824
-23,800
-63% -$6.2M 0.12% 69
2024
Q2 		$9.14M Buy
37,624
+4,964
+15% +$784K 0.34% 52
2024
Q1 		$4.88M Buy
32,660
+22,800
+231% +$3.8M 0.18% 63
2023
Q4 		$1.89M Buy
+9,860
New +$1.68M 0.09% 65

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aaron Cowen's ALNY Position: Q2 2025 in Review

Aaron Cowen sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 9,370 shares — an estimated $2.53M sold.

Aaron Cowen first reported a position in ALNY in Q4 2023 and held it in 5 quarters. The position peaked at $9.14M in Q2 2024. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Aaron Cowen reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Aaron Cowen sold 9,370 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $2.53M.
  • Aaron Cowen first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Aaron Cowen's Alnylam Pharmaceuticals position peaked at $9.14M in Q2 2024.
  • 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Suvretta Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.